Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?

Key Takeaways EXAS posted 14% Q1 screening revenue growth, fueled by rising Cologuard rescreens and new provider adoption. Launches like Cologuard Plus and Oncodetect MRD aim to expand EXAS' footprint in cancer diagnostics. Despite $786M in cash, EXAS faces pressure from$2.32B in long-term debt and global macro headwinds.Exact Sciences Corporation’s (EXAS) efforts to further promote its flagship Cologuard as the standard of care are encouraging. The company plans to transform cancer care by providing pat ...